Market Place
Sourcing Support
Indivior Data Shows SUBLOCADE® Supports Long-Term Recovery
30 Oct 2024 //
PR NEWSWIRE
Indivior`s Sublocade Receives FDA Priority Review For Injection Site
07 Oct 2024 //
PR NEWSWIRE
Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine HCL
22 May 2024 //
FDA
Purdue Pharma partners with MMCAP Infuse to provide low-cost opioid use disorder
08 May 2024 //
PHARMABIZ
DifGen Pharmaceuticals Successfully Launches A Second Product - Buprenorphine
02 Nov 2023 //
PR NEWSWIRE
Indivior to fork over $385M in Suboxone antitrust settlement
24 Oct 2023 //
FIERCE PHARMA
IntelGenx Provides Regulatory Update for Buprenorphine Buccal Film
19 Sep 2023 //
GLOBENEWSWIRE
Orexo`s patent win for ZUBSOLV® appealed
24 Jul 2023 //
PR NEWSWIRE
Orexo wins patent litigation for ZUBSOLV® in the US
01 Jul 2023 //
PR NEWSWIRE
Over 40% of U.S. Pharmacies Report No Buprenorphine in Stock
07 Jun 2023 //
GLOBENEWSWIRE
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
24 May 2023 //
PR NEWSWIRE
IntelGenx Announces Receipt of CRL from the FDA for Xiromed Buprenorphine
27 Apr 2023 //
GLOBENEWSWIRE
Clinicians Identify Buprenorphine “Spiking” In JAMA Psychiatry Study Supported
22 Mar 2023 //
BUSINESSWIRE
Enforcement Report - Week of March 22, 2023
22 Mar 2023 //
FDA
FDA Accepts Braeburn`s NDA Resubmission for BRIXADI Subcutaneous Injection
08 Dec 2022 //
PRNEWSWIRE
Enforcement Report - Week of November 9, 2022
09 Nov 2022 //
FDA
Indivior fails to escape class action lawsuit in Suboxone case
24 Aug 2022 //
ENDPTS
Buprenorphine treatment for veterans with opioid use disorder increased
28 Jul 2022 //
STATNEWS
Alvogen Pine Brook Generic Buprenorphine Receives Approval In US
17 May 2022 //
FDA
Millennium Health, the University of Cincinnati Conducting NIDA-Funded Research
10 May 2022 //
BUSINESSWIRE
PureTech Publishes Research from Collaborators on PureTech’s Glyph Platform
12 Apr 2022 //
BUSINESSWIRE
Buprenorphine Mitigates Fentanyl-Induced Respiratory Depression in Opioid Users
08 Apr 2022 //
PRNEWSWIRE
Orexo`s lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List
24 Feb 2022 //
PRNEWSWIRE
High Plasma Concentrations of Buprenorphine Reduce Respiratory Depression
27 Jan 2022 //
PRNEWSWIRE
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance
20 Jan 2022 //
GLOBENEWSWIRE
Offering buprenorphine medication to people with opioid use disorder in jail
18 Jan 2022 //
NIH
FDA flags risk of dental issues from use of opioid addiction drug buprenorphine
13 Jan 2022 //
REUTERS
Hikma`s Generic Everolimus Receives Approval in the US
23 Nov 2021 //
FDA
DEA-Wary Pharmacies Shy From Dispensing Addiction Medication
09 Nov 2021 //
KHN
Aveva`s Generic Buprenorphine Receives Approval in the US
23 Sep 2021 //
FDA
Alvogen`s Generic Buprenorphine HCl Receives Approval In US
03 Aug 2021 //
FDA
Enforcement Report - Week of July 14, 2021
14 Jul 2021 //
FDA
Pear Therapeutics Announces First Participant Enrolled in NIH Clinical Trial
29 Jun 2021 //
BIOSPACE
Sanyou Biopharmaceuticals completes series B financing
26 Jun 2021 //
PR NEWSWIRE
Braeburn Resubmits New Drug Application for BRIXADI
15 Jun 2021 //
PRNEWSWIRE
Mylan Technologies`s Generic Buprenorphine Receives Approval In US
06 May 2021 //
FDA
As Opioid Deaths Surge, Biden Team Moves To Make Buprenorphine Mainstream
28 Apr 2021 //
NPR
AcelRx Announces an Investigator-Initiated Study of DSUVIA®
08 Apr 2021 //
PRNEWSWIRE
Indivior faces suit from former parent RB over Suboxone scheme
02 Dec 2020 //
FIERCE PHARMA
Enforcement Report for Week of October 7, 2020
07 Oct 2020 //
FDA
Indivior Takes Strategic Alignment Actions
23 Sep 2020 //
BIOSPACE
Enforcement Report - Week of September 2, 2020
02 Sep 2020 //
FDA
When Prescribing Isn’t Enough — Pharmacy-Level Barriers to Buprenorphine Access
21 Aug 2020 //
NEJM
Braeburn Submits Request for Final Approval of BRIXADI™ (buprenorphine
01 Jun 2020 //
PRNEWSWIRE
SUBLOCADE® Long-Term Safety Data Published in Journal of Clinical
16 Apr 2020 //
PR NEWSWIRE
Amneal Pharmaceuticals Generic Buprenorphine Receives Approval in US
16 Apr 2020 //
FDA
Orphan Drug Act’s ‘nonprofitability’ loophole needs to be closed
19 Dec 2019 //
STATNEWS
New Analysis From One-Year Study of Monthly Buprenorphine ER Injections
02 Dec 2019 //
PR NEWSWIRE
Camurus Announces Superior Patient Reported Outcomes With Buvidal
26 Nov 2019 //
PR NEWSWIRE
Camurus Announces Results Showing Superior Outcomes With Buvidal®
25 Nov 2019 //
PR NEWSWIRE
FDA to Revoke Orphan Designation for Opioid Addiction Drug Sublocade
09 Nov 2019 //
RAPS
Braeburn to seek US FDA marketing nod for Brixadi ER injection
08 Nov 2019 //
PHARMABIZ
Teva offers $23B of Suboxone to get out of opioid litigation
22 Oct 2019 //
BIOPHARMADDIVE
Product Hopping: E&C Hearing Addresses Restrictions to Generic Competition
19 Sep 2019 //
RAPS
Beset by lawsuits and criticism in U.S., opioid makers eye new market in India
31 Aug 2019 //
FIERCE PHARMA
Major drug bust at Faridkot by FDA, CIA teams
29 Aug 2019 //
INDIANEXPRESS
Orexo partners with Gaia on digital opioid abuse therapeutic
23 Aug 2019 //
PHARMAPHORUM
SMC rejects Orkambi, accepts four medicines
13 Aug 2019 //
PHARMA TIMES
FDA ordered to reconsider Braeburn`s application for final approval of Brixadi
24 Jul 2019 //
THE PHARMALETTER
Reckitt Benckiser Settles Indivior Opioid Investigation for $1.4 Billion
12 Jul 2019 //
BIOSPACE
